Gastrointestinal Therapeutics Market Size, Share & Trends Analysis Report By Type, By Drug Class, By Application (Crohn’s Disease, Ulcerative Colitis, GERD), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 203

Gastrointestinal Therapeutics Market Size, Share & Trends Analysis Report By Type, By Drug Class, By Application (Crohn’s Disease, Ulcerative Colitis, GERD), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

Gastrointestinal Therapeutics Market Growth & Trends

The global gastrointestinal therapeutics market size is expected to reach USD 48.61 billion by 2030, advancing at a CAGR of 3.3% during the forecast period, as per a new report by Grand View Research, Inc. Unhealthy eating habits, coupled with a sedentary lifestyle, have led to the development of gastrointestinal diseases among consumers, which is expected to drive market growth. Moreover, the rising adoption of biologics for the treatment of GI disorders is also fueling growth. For instance, REMICADE (Infliximab) by Janssen Biotech, Inc., and other biological drugs have been approved for the treatment of Crohn’s disease and ulcerative colitis.

The increasing incidences of industry-academia collaborations to promote gastrointestinal research and develop novel therapies for patients with GI disorders will likely facilitate market expansion. For instance, in November 2020, Takeda Pharmaceutical Company Limited, Columbia University, and New York University formed a collaborative research alliance to advance gastroenterology research programs, to develop new therapeutics for gastrointestinal diseases.

Moreover, market growth is also anticipated to increase research & development initiatives by government and private organizations for the development of new gastrointestinal drugs. As of November 2022, according to the U.S. National Library of Medicine, there were 7,586 ongoing clinical studies (including observational studies, drug development, and others) related to gastrointestinal diseases, at various stages of development. Moreover, in May 2022, AbbVie Inc. announced positive topline results from a phase-3 study that is evaluating upadacitinib in adult patients with severe to moderate Crohn's disease, who were intolerant to biologic therapy.

The presence of government and non-profit organizations that support gastrointestinal research, offer to fund studies, and promote awareness about GI disorders, is anticipated to augment GI therapeutics market growth. For instance, the International Foundation for Gastrointestinal Disorders, GI- research foundation, and American Gastroenterological Association are some of the key organizations supporting research activities and increasing awareness about gastrointestinal diseases among people. These organizations also raise funds for ongoing GI research activities.

Furthermore, various strategic initiatives such as product launches, collaboration, mergers, and acquisitions undertaken by leading players are expected to offer lucrative opportunities for market growth. For instance, in July 2022, Eli Lilly announced a partnership with the Chinese drug 3D printing firm to develop and research 3D-printed oral drugs for the GI tract application.

In addition, in April 2020acquired global rights, excluding Canada, Europe, and Israel, of Movantik (naloxegol) by AstraZeneca, for the management of opioid-induced constipation. This acquisition is expected to strengthen the company’s position in the global gastrointestinal therapeutics industry.

Gastrointestinal Therapeutics Market Report Highlights

• Branded drugs held the largest share in the drug type segment in 2022, owing to high market penetration, ongoing product approvals, and extensive R&D efforts by pharma companies
• The generic drugs segment is expected to register the fastest growth rate through the forecast period, because of the rising patent expiration of branded drugs and the cost-effectiveness of generics
• In terms of drug class, the biologics/biosimilar segment accounted for the largest market share in 2022 due to extensive applications of biologics in severe GI diseases such as Crohn’s disease and ulcerative colitis
• Based on application, the Crohn’s disease segment dominated the GI therapeutics market in 2022, whereas the ulcerative colitis segment is anticipated to be the fastest-growing segment
• The retail pharmacy segment held the largest market revenue share in 2022, due to the easy accessibility to retail stores and the rising penetration of OTC drugs
• Asia Pacific is expected to exhibit the fastest growth during the forecast period due to the rising investments by market players and increasing disease prevalence in the region

Please note The report will be delivered in 2-3 business days upon order notification. Show more